查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
精準醫療市場 - 全球和區域分析：按生態系統、應用和區域 - 分析和預測（2024-2034 年）
市場調查報告書
商品編碼
1654120

精準醫療市場 - 全球和區域分析：按生態系統、應用和區域 - 分析和預測（2024-2034 年）

Precision Medicine Market - A Global and Regional Analysis: Focus on Ecosystem, Application, and Region - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 287 Pages | 商品交期: 1-5個工作天內

價格

精準醫療利用個人的臨床、分子和生活方式資料來幫助診斷、治療和預防癌症、遺傳疾病和其他複雜疾病。

精準醫療代表著醫療保健領域的變革性轉變，從傳統的「一刀切」治療方法轉向更客製化、更有針對性的治療策略。透過利用基因組學、分子診斷和資料分析方面的進步，醫療保健提供者可以根據個人的遺傳、環境和生活方式因素制定個人化的治療計劃。這種方法不僅有望提高治療效果，還能減少不必要的試驗，從而改善患者的治療效果並降低醫療成本。隨著該領域的不斷發展，大規模人口研究和最尖端科技正在為更準確的疾病預測、早期診斷和最佳化治療性介入鋪平道路。

主要市場統計數據
預測期 2024-2034
2024 年評估 1515.7億美元
2034 年預測 4691.6億美元
複合年成長率 11.96％

全球精準醫療市場預計將大幅成長，到 2034 年將達到 4,690 億美元。精準醫療的興起是由多體學研究的擴展所推動的，它結合基因組學、蛋白質組學、代謝體學和其他分子資料，以更全面地了解健康和疾病。這種創新方法在腫瘤學、藥物基因組學和遺傳疾病等各個治療領域中具有巨大潛力。

由於定序技術的進步、定序成本的下降以及個人化醫療趨勢的變化，精準醫療市場正在快速成長。此外，基因定序和基因編輯的進步，特別是使用 CRISPR 和次世代定序(NGS)，正在透過實現更有針對性的個人化治療來推動精準醫療的發展。這些技術使更有效的癌症治療成為可能，例如CAR-T細胞療法，它利用患者的免疫系統來對抗癌症。隨著這些技術的發展，有望進一步提高診斷的準確性，促進早期療育，最佳化治療結果，從而促進腫瘤學和遺傳疾病領域精準醫療解決方案的需求不斷成長。

此外，時空體學技術和蛋白質組學已成為在分子層面上理解複雜疾病的重要工具。透過分析基因組、蛋白質組和代謝體學學中的突變，這些技術可以深入了解癌症等疾病的異質性，為根據每個人獨特的疾病特徵制定治療方案鋪平了道路。人工智慧（AI）、巨量資料分析和物聯網技術的整合也透過實現對患者資料的即時監控和分析，改變了精準醫療格局。這些進步將提高我們預測疾病進展、個人化治療和改善患者預後的能力。然而，資料隱私問題和對先進運算工具的需求等挑戰可能會影響市場上精準醫療解決方案的整體採用和擴充性。隨著這些技術的成熟，預計精準醫療的進一步創新將帶來更有效率、更有效的醫療保健模式。

本報告研究了全球精準醫療市場，並提供了市場概述、生態系統和應用趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章 市場概況

第2章市場：產業展望

  • 全球精準醫療市場：生態系分析
  • 市場趨勢
  • 市場動態概覽
  • 業界考察
  • 生態系概覽
  • 市場概況
  • 應用科學
  • 精準診斷
  • 數位健康與資訊技術
  • 精準醫療

第3章 用途

  • 應用概述
  • 概述
  • 瘤
  • 感染疾病
  • 神經
  • 心血管
  • 生活方式和內分泌學
  • 胃腸病學
  • 其他

第4章 區域

  • 概述
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第5章 競爭格局

  • 競爭格局
  • 公司簡介
    • Abbott
    • Thermo Fisher Scientific, Inc.
    • Almac Group
    • ANGLE plc
    • Astellas Pharma Inc
    • Bio-Rad Laboratories, Inc.
    • Epic Sciences
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • Illumina, Inc.
    • QIAGEN NV
    • Sysmex Corporation
    • Laboratory Corporation of America Holdings
    • Danaher Corporation
    • Quest Diagnostics
    • AstraZeneca
    • ASURAGEN, INC
    • bioMerieux SA
    • Bristol-Myers Squibb
    • Pacific Biosciences of California, Inc.
    • Myriad Genetics, Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Sanofi SA
    • Randox Laboratories Ltd.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Konica Minolta, Inc.
    • Cardiff Oncology
    • GE HealthCare
    • Gilead Science, Inc.
    • GSK plc
    • Johnson & Johnson
    • MDx Health, Inc.
    • Novartis AG
    • Oracle Corporation
    • Menarini Silicon Biosystems

第6章調查方法

Product Code: BHP0347SF

Introduction of Precision Medicine

Precision medicine utilizes an individual's distinct clinical, molecular, and lifestyle data to inform the diagnosis, treatment, and prevention of cancer, inherited diseases, and other complex conditions. Precision medicine represents a transformative shift in healthcare, moving away from the traditional one-size-fits-all approach to a more tailored and targeted therapeutic strategy. By leveraging advancements in genomics, molecular diagnostics, and data analytics, precision medicine enables healthcare providers to craft personalized treatment plans based on an individual's genetic, environmental, and lifestyle factors. This approach not only promises to enhance the effectiveness of treatments but also reduces unnecessary trial-and-error, leading to better patient outcomes and reduced healthcare costs. As the field continues to evolve, large-scale population studies and cutting-edge technologies are paving the way for more accurate disease predictions, early diagnoses, and optimized therapeutic interventions.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$151.57 Billion
2034 Forecast$469.16 Billion
CAGR11.96%

The global precision medicine market is expected to witness substantial growth, projected to reach $469 billion by 2034. The growing adoption of precision medicine has been fueled by the expansion of multi-omics research, which combines genomics, proteomics, metabolomics, and other molecular data to create a more comprehensive understanding of health and disease. This innovative approach holds significant potential in various therapeutic areas, including oncology, pharmacogenomics, and inherited diseases.

The precision medicine market has been experiencing rapid growth driven by advancements in sequencing technologies, decreasing sequencing costs, shifting trends toward personalized health, etc. Moreover, advancements in gene sequencing and editing, particularly with CRISPR and next-generation sequencing (NGS), are driving precision medicine forward by enabling more targeted and personalized treatments. These technologies allow for more effective cancer therapies, such as CAR-T cell therapy, which harnesses the patient's immune system to fight cancer. As these technologies evolve, they are expected to further enhance the accuracy of diagnoses, facilitate early interventions, and optimize therapeutic outcomes, contributing to the growing demand for precision medicine solutions in oncology and genetic disorders.

In addition, spatiotemporal omics technologies and proteomics have emerged as critical tools for understanding complex diseases at a molecular level. By analyzing variations in genomic, proteomic, and metabolomic profiles, these technologies provide deeper insights into the heterogeneity of diseases such as cancer, paving the way for treatments tailored to an individual's unique disease characteristics. The integration of artificial intelligence (AI), big data analytics, and IoT technologies has also been transforming the precision medicine landscape by enabling real-time monitoring and analysis of patient data. These advancements improve the ability to predict disease progression, personalize treatments, and enhance patient outcomes. However, they also introduce challenges, such as data privacy concerns and the need for advanced computational tools, which could impact the overall adoption and scalability of precision medicine solutions in the market. As these technologies mature, they will drive further innovation in the precision medicine space, leading to more efficient and effective healthcare models.

Industrial Impact

Precision medicine is reshaping the healthcare industry by enabling personalized treatments that significantly improve patient outcomes. For instance, the use of genetic profiling in oncology has led to the development of targeted therapies such as Herceptin for breast cancer, which is specifically designed to treat patients with HER2-positive tumors. In addition to improving individual patient care, precision medicine is driving innovation across the healthcare ecosystem, particularly in drug discovery and clinical trials. The pharmaceutical industry is leveraging genomics to discover new drug targets, as seen in the development of the breakthrough drug Kymriah, a CAR-T therapy for leukemia, which was developed through the identification of genetic markers specific to the disease. Clinical trials are also becoming more targeted, with companies such as Novartis and Pfizer using genomic data to stratify patient populations and improve trial efficiency. Moreover, the integration of precision medicine into population health management is evident in initiatives such as Geisinger Health System's MyCode Community Health Initiative, which offers genomic sequencing to patients to improve preventive care and early disease detection. This growing application of precision medicine has not only improved individual treatment outcomes but has also helped to optimize healthcare delivery systems, reduce costs, and accelerate the development of new therapies.

Market Segmentation

Segmentation 1: by Ecosystem

  • Applied Science
    • Genomics
    • Pharmacogenomics
    • Other Applied Science
  • Precision Diagnostics
    • Molecular Diagnostics
    • Medical Imaging
  • Digital Health and Information Technology
    • Clinical Decision Support Systems (CDSS)
    • Big Data Analytics
    • IT Infrastructure
    • Genomics Informatics
    • In-Silico Informatics
    • Mobile Health
  • Precision Therapeutics
    • Clinical Trials
    • Cell Therapy
    • Drug Discovery and Research
    • Gene Therapy

In the global precision medicine market, as of 2023, the precision therapeutics segment holds the largest share at 33.6%. Precision therapeutics has gained significant traction in oncology, rare diseases, and chronic conditions, where traditional treatments often fall short due to its ability to offer highly personalized treatment options that are tailored to an individual's genetic, molecular, and environmental profiles. Moreover, the growing use of biomarker-driven patient selection in clinical trials further enhances treatment efficacy, as it helps identify the right patients for the right therapies, reducing trial failure rates and accelerating the path to successful treatments. On the other hand, the digital health and IT infrastructure segment is projected to grow at the highest (CAGR) of 14.4% from 2024 to 2034 Digital health is becoming an increasingly important part of precision medicine due to its ability to enhance patient care through the collection, transmission, and integration of vast amounts of personalized health data. Moreover, it allows for the real-time tracking of a patient's health, enabling quick modifications to treatment plans as needed. This continuous feedback loop ensures that therapies remain optimal throughout the course of treatment, helping to improve patient outcomes.

Segmentation 2: by Application

  • Oncology
  • Infectious Diseases
  • Neurology/Psychiatry
  • Life Style and Endocrinology
  • Cardiology
  • Gastroenterology
  • Others

Based on application, the global precision medicine market was led by the oncology segment, which held a 52.8% share in 2023. The global increase in cancer burden has been one of the major factors driving the demand for precision medicine. For instance, according to the World Health Organization, more than 35 million new cancer cases are expected by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Moreover, technological advancements, especially in genomic sequencing and molecular diagnostics, have transformed cancer treatment. Next-generation sequencing (NGS) identifies genetic alterations and biomarkers, enabling personalized therapies tailored to a patient's tumor characteristics. In addition, the growing integration of genomic data into immunotherapy, where treatments are increasingly guided by specific genetic or molecular markers that predict how patients will respond to immune-based treatments, is driving the segment growth.

Segmentation 3: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • K.S.A.
    • South Africa
    • Rest-of-Middle East and Africa

The precision medicine market in the North America region is expected to witness a significant growth rate of 10.25% during the forecast period, marked by the increasing prevalence of genetic disorders and the growing demand for personalized medicine and robust government initiatives. Also, the strong infrastructure for medical research and clinical trials and increasing investment by biopharmaceutical companies in precision medicine are driving the market. However, the Asia-Pacific region is expected to witness the fastest growth rate of 14.67% during the forecast period 2024-2034 Various factors are expected to contribute to this growth, including increasing disposable income, rising prevalence of chronic disease, increasing demand for personalized health, and increasing focus on the development of cost-effective, advanced diagnostic tools.

Recent Developments in the Precision Medicine Market

  • In January 2025, OMNY Health and Scipher Medicine entered into a partnership to advance precision medicine in autoimmune diseases. Under this partnership, Scipher Medicine will combine its clinico-transcriptomic data with OMNY Health's vast electronic medical record (EMR) network to enhance treatment options and outcomes for millions of patients worldwide.
  • In November 2024, 23andMe Holding Co. and Mirador Therapeutics entered into a strategic research collaboration. Through this partnership, Mirador will utilize a curated set of de-identified genetic and phenotypic data from the 23andMe research database, combined with its proprietary Mirador360 development engine, to advance target validation and precision medicine initiatives.
  • In May 2024, the Precision Health Alliance, a new initiative co-founded by the Duke Clinical Research Institute (DCRI), Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Verve Therapeutics, was launched to drive innovation in precision health and medicine. The alliance aims to address challenges in personalized healthcare by focusing on genetic factors and will serve as a collaborative platform for research in gene editing. It seeks to explore patient preferences, ethical issues, and regulatory challenges while influencing future policies and payment models to expand patient access and accelerate advancements in the field.
  • In May 2024, Rymedi and Precision Genetics announced a strategic partnership to enhance health outcomes and efficiencies through precision medicine. This collaboration will integrate Precision Genetics' PrecisionOp, a personalized solution to minimize adverse drug reactions and reduce opioid use after surgery, with Rymedi's blockchain-enabled clinical trial and registry platform.

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

Advancement of Sequencing Technologies: The advancement of DNA sequencing technologies has been a key driver in the rapid growth of the precision medicine market, bringing transformative changes to healthcare. From the early days of Sanger sequencing to the innovations in next-generation sequencing (NGS) and long-read technologies, sequencing methods have become more accurate, personalized, and efficient. The dramatic reduction in sequencing costs, from over $100 million in 2001 to just $100-$200 in 2023, has made genomic testing more accessible and integrated into routine clinical care. This affordability is crucial in expanding precision medicine's reach to a broader patient base. Advances in sequencing accuracy, especially with long-read technologies, have enhanced the identification of rare genetic variants and allowed for more precise diagnoses and treatments, particularly in complex conditions such as cancer, cardiovascular diseases, and genetic disorders. Additionally, improvements in sequencing speed and throughput enable faster, large-scale genetic studies, while multi-omics integration provides a more holistic approach to personalized treatment. These developments are accelerating the demand for precision medicine, making genomic testing a core component of modern healthcare.

Market Challenges:

Data Integration and Interoperability Issues: A key challenge in precision medicine is integrating diverse data sources to create a comprehensive view of a patient's health. Healthcare providers must combine electronic health records (EHRs), genomic databases, imaging data, patient-reported outcomes (PROs), and other relevant datasets, but these are often stored in siloed systems that lack seamless communication. Data silos remain a significant barrier, with platforms used for clinical, genomic, and imaging data often unable to interact effectively. A 2023 HealthIT.gov survey revealed that 40% of healthcare organizations struggle to fully integrate EHRs with external data sources, such as genomic and imaging information. This fragmentation hinders personalized decision-making, as healthcare providers cannot easily access or correlate the necessary data. The complexity of data integration is further compounded by the need for specialized tools to analyze genomic data, natural language processing (NLP) to structure clinical notes and advanced imaging software for aligning data. Additionally, many healthcare systems overlook the integration of PROs, which are critical for understanding a patient's lifestyle and preferences, with over 35% of providers not yet incorporating them into clinical workflows, limiting the ability to offer truly personalized care.

Market Opportunities:

AI Integration in Precision Medicine: The integration of AI into precision medicine (PM) offers a significant opportunity for market growth by enhancing various aspects of healthcare, including risk assessment, treatment optimization, and patient outcomes. AI's ability to process complex biological data, including genetic profiles and patient histories, overcomes traditional barriers to robust risk assessment protocols, enabling more accurate predictions and personalized care. For instance, AI has revolutionized disease diagnosis by identifying patterns that may be missed by human clinicians, particularly in fields like dermatology and Alzheimer's disease. It also improves patient monitoring by leveraging data from wearables and IoT sensors to provide real-time insights, reducing diagnostic errors and enabling timely interventions. Furthermore, AI accelerates drug discovery by analyzing large datasets to identify new therapeutic targets, particularly in cancer, ultimately enhancing the precision and effectiveness of treatments. Integrating AI into clinical decision-making improves diagnostic accuracy and supports clinicians with evidence-based insights, ensuring more informed decisions.

Market Trends:

Integrating Advanced Imaging for Enhanced Diagnostics and Treatment

The trend in precision medicine is shifting toward delivering high-quality, personalized care through the integration of advanced imaging technologies, genomics, and AI-driven solutions. This approach enhances the accuracy and effectiveness of diagnoses and treatment plans by offering a multi-dimensional understanding of diseases such as cancer. Radiomics and AI are transforming clinical decision-making by providing actionable insights from medical images, enabling a deeper understanding of tumor heterogeneity and patient-specific factors. Additionally, cloud-based platforms and biophysical modeling are allowing for real-time analysis and personalized treatment simulations, further improving clinical outcomes. As these technologies evolve, the demand for high-quality, tailored therapies is expected to rise, offering better results than traditional methods.

Analyst's Thoughts

According to Akash Mhaskar, Principal Analyst - BIS Research, "The precision medicine market is growing rapidly, fueled by advancements in DNA sequencing technologies that make genomic testing more accessible. Despite challenges in data integration, AI offers significant opportunities by enhancing disease diagnosis, risk assessment, and treatment optimization. As AI and sequencing technologies evolve, precision medicine is set to transform patient care, especially in oncology and genetic disorders."

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Market Definition
  • 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
  • 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • 1.4 Initiatives and Programs
  • 1.5 Precision Medicine: Enabling Technologies and Applications
    • 1.5.1 Innovators
      • 1.5.1.1 3D DNA Printing
        • 1.5.1.1.1 Introduction
        • 1.5.1.1.2 Role of 3D DNA Printing
      • 1.5.1.2 RNA-Seq
        • 1.5.1.2.1 Introduction
        • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
        • 1.5.1.2.3 Key Players
      • 1.5.1.3 4D Molecular Imaging
        • 1.5.1.3.1 Introduction
        • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
        • 1.5.1.3.3 Key Players
    • 1.5.2 Early Adopters
      • 1.5.2.1 CRISPR
        • 1.5.2.1.1 Introduction
        • 1.5.2.1.2 Role of CRISPR in Precision Medicine
        • 1.5.2.1.3 Key Players
      • 1.5.2.2 Blockchain
        • 1.5.2.2.1 Introduction
        • 1.5.2.2.2 Role of Blockchain in Precision Medicine
        • 1.5.2.2.3 Key Players
      • 1.5.2.3 Imaging Informatics
        • 1.5.2.3.1 Introduction
        • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
        • 1.5.2.3.3 Key Players
    • 1.5.3 Early Majority
      • 1.5.3.1 Artificial Intelligence (AI)
        • 1.5.3.1.1 Introduction
        • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
        • 1.5.3.1.3 Key Players
      • 1.5.3.2 Circulating Free DNA (cfDNA)
        • 1.5.3.2.1 Introduction
        • 1.5.3.2.2 Role of cfDNA in Precision Medicine
        • 1.5.3.2.3 Key Players
      • 1.5.3.3 Big Data
        • 1.5.3.3.1 Introduction
        • 1.5.3.3.2 Role of Big Data in Precision Medicine
        • 1.5.3.3.3 Key Players
      • 1.5.3.4 Next-Generation Sequencing (NGS)
        • 1.5.3.4.1 Introduction
        • 1.5.3.4.2 Role of NGS in Precision Medicine
        • 1.5.3.4.3 Key Players
      • 1.5.3.5 Health Informatics
        • 1.5.3.5.1 Introduction
        • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
        • 1.5.3.5.3 Key players
      • 1.5.3.6 Bioinformatics
        • 1.5.3.6.1 Introduction
        • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
        • 1.5.3.6.3 Key Players
    • 1.5.4 Late Majority
      • 1.5.4.1 Polymerase Chain Reactions (PCR)
        • 1.5.4.1.1 Introduction
        • 1.5.4.1.2 Role of PCR in Precision Medicine
        • 1.5.4.1.3 Key players
      • 1.5.4.2 Microarray
        • 1.5.4.2.1 Role of Microarray in Precision Medicine
        • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

  • 2.1 Global Precision Medicine Market: Ecosystem Analysis
  • 2.2 Market Trends
    • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
    • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
  • 2.3 Market Dynamics Overview
    • 2.3.1 Market Drivers
      • 2.3.1.1 Advancement of Sequencing Technologies
      • 2.3.1.2 Rising Prevalence of Chronic Disease across the Globe
      • 2.3.1.3 Potential to Reduce Healthcare Costs across the Globe
      • 2.3.1.4 Potential to Reduce Adverse Drug Reaction through Pharmacogenomic Testing
    • 2.3.2 Market Restraints
      • 2.3.2.1 Data Integration and Interoperability Issues
      • 2.3.2.2 High Costs and Limited Accessibility
      • 2.3.2.3 Limited Reimbursement and Insurance Coverage
    • 2.3.3 Market Opportunities
      • 2.3.3.1 AI Integration in Precision Medicine
      • 2.3.3.2 Increasing Collaborations and Partnerships
  • 2.4 Industry Insights
    • 2.4.1 Patent Analysis
    • 2.4.2 Pipeline Analysis
    • 2.4.3 Legal Requirements and Regulations
    • 2.4.4 Legal Requirements and Framework by FDA
    • 2.4.5 Legal Requirements and Framework by the EMA
    • 2.4.6 Legal Requirements and Framework by the MHLW
  • 2.5 Ecosystem Summary
  • 2.6 Market Overview
  • 2.7 Applied Sciences
    • 2.7.1 Genomics
    • 2.7.2 Global Precision Medicine Market (by Applied Science) (by Genomics)
      • 2.7.2.1 Polymerase Chain Reaction (PCR)
        • 2.7.2.1.1 Global Precision Medicine PCR Market (by Product)
        • 2.7.2.1.2 Global Precision Medicine PCR Market (by End User)
        • 2.7.2.1.3 Global Precision Medicine PCR Market (by Region)
      • 2.7.2.2 Next-Generation Sequencing (NGS)
        • 2.7.2.2.1 Global Precision Medicine NGS Market (by Product)
        • 2.7.2.2.2 Global Precision Medicine NGS Market (by Technology)
        • 2.7.2.2.3 Global Precision Medicine NGS Market (by End User)
        • 2.7.2.2.4 Global Precision Medicine NGS Market (by Region)
      • 2.7.2.3 Genome Editing
        • 2.7.2.3.1 Global Precision Medicine Genome Editing Market (by Product)
        • 2.7.2.3.2 Global Precision Medicine Genome Editing Market (by End User)
        • 2.7.2.3.3 Global Precision Medicine Genome Editing Market (by Region)
      • 2.7.2.4 Other Technologies
        • 2.7.2.4.1 Global Precision Medicine Other Technologies Market (by Region)
    • 2.7.3 Pharmacogenomics
      • 2.7.3.1 Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services)
      • 2.7.3.2 Global Precision Medicine Pharmacogenomics Market (by End User)
      • 2.7.3.3 Global Precision Medicine Pharmacogenomics Market (by Region)
    • 2.7.4 Other Applied Sciences
  • 2.8 Precision Diagnostics
    • 2.8.1 Molecular Diagnostics (MDx)
    • 2.8.2 Global Precision Medicine Market (by Molecular Diagnostics (by Type)
      • 2.8.2.1 Non-Invasive Prenatal Testing (NIPT)
        • 2.8.2.1.1 Global Precision Medicine NIPT Market (by Platform)
        • 2.8.2.1.2 Global Precision Medicine NIPT Market (by Region)
      • 2.8.2.2 Companion Diagnostics
        • 2.8.2.2.1 Global Precision Medicine Companion Diagnostics Market (by Technology)
        • 2.8.2.2.2 Global Precision Medicine Companion Diagnostics Market (by Indication)
        • 2.8.2.2.3 Global Precision Medicine Companion Diagnostics Market (by Region)
      • 2.8.2.3 Liquid Biopsy
        • 2.8.2.3.1 Global Precision Medicine Liquid Biopsy Market (by Indication)
        • 2.8.2.3.2 Global Precision Medicine Liquid Biopsy Market (by Region)
      • 2.8.2.4 Other Molecular Diagnostics
        • 2.8.2.4.1 Global Precision Medicine Other Molecular Diagnostics Market (by Type)
        • 2.8.2.4.2 Global Precision Medicine Other Molecular Diagnostics Market (by Region)
    • 2.8.3 Medical Imaging
      • 2.8.3.1 Global Precision Medicine Market (by Precision Diagnostics) (by Medical Imaging) (by Type)
        • 2.8.3.1.1 Imaging Analytics
        • 2.8.3.1.2 Imaging Computer-Aided Detection (CADx)
      • 2.8.3.2 Global Precision Medicine Market (by Precision Diagnostics) (by Medical Imaging) (by Region)
  • 2.9 Digital Health and Information Technology
    • 2.9.1 Global Precision Medicine Market (by Digital Health and Information Technology) (by Type)
      • 2.9.1.1 Clinical Decision Support Systems (CDSS)
      • 2.9.1.2 Big Data Analytics
      • 2.9.1.3 IT Infrastructure
        • 2.9.1.3.1 Global Precision Medicine Market (by Digital Health and Information Technology) (by IT Infrastructure) (by Type)
      • 2.9.1.4 Genomics Informatics
        • 2.9.1.4.1 Global Precision Medicine Market (by Digital Health and Information Technology) (by Genomics Informatics) (by Product Type)
      • 2.9.1.5 In-Silico Informatics
      • 2.9.1.6 Mobile Health
    • 2.9.2 Global Precision Medicine Market (by Digital Health and Information Technology) (by End User)
    • 2.9.3 Global Precision Medicine Market (by Digital Health and Information Technology ) (by Region)
  • 2.1 Precision Therapeutics
    • 2.10.1 Global Precision Medicine Market (by Precision Therapeutics)
      • 2.10.1.1 Clinical Trials
        • 2.10.1.1.1 Global Precision Medicine Market (by Precision Therapeutics) (by Clinical Trials) (by Region)
      • 2.10.1.2 Cell Therapy
        • 2.10.1.2.1 Global Precision Medicine Market (by Precision Therapeutics) (by Cell Therapy) (by Region)
      • 2.10.1.3 Drug Discovery and Research
        • 2.10.1.3.1 Global Precision Medicine Market (by Precision Therapeutics) (by Drug Discovery and Research) (by Region)
      • 2.10.1.4 Gene Therapy
        • 2.10.1.4.1 Global Precision Medicine Market (by Precision Therapeutics) (by Gene Therapy) (by Region)

3 Application

  • 3.1 Application Summary
  • 3.2 Overview
  • 3.3 Oncology
    • 3.3.1 Global Precision Medicine Market (by Oncology)
  • 3.4 Infectious Diseases
    • 3.4.1 Global Precision Medicine Market (by Infectious Disease)
  • 3.5 Neurology
    • 3.5.1 Global Precision Medicine Market (by Neurology)
  • 3.6 Cardiovascular
    • 3.6.1 Global Precision Medicine Market (by Cardiovascular Disease)
  • 3.7 Lifestyle and Endocrinology
    • 3.7.1 Global Precision Medicine Market (by Lifesctyle and Endocrinology)
  • 3.8 Gastroenterology
    • 3.8.1 Global Precision Medicine Market (by Gastroenterology)
  • 3.9 Other Applications
    • 3.9.1 Global Precision Medicine Market (by Other Application)

4 Region

  • 4.1 Overview
  • 4.2 North America
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
      • 4.2.3.1 Ecosystem
    • 4.2.4 U.S.
      • 4.2.4.1 U.S. Precision Medicine Market (by Ecosystem),
    • 4.2.5 Canada
      • 4.2.5.1 Canada Precision Medicine Market (by Ecosystem)
  • 4.3 Europe
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
      • 4.3.3.1 Europe Precision Medicine Market (by Ecosystem),
    • 4.3.4 Germany
      • 4.3.4.1 Germany Precision Medicine Market (by Ecosystem),
    • 4.3.5 France
      • 4.3.5.1 France Precision Medicine Market (by Ecosystem)
    • 4.3.6 Italy
      • 4.3.6.1 Italy Precision Medicine Market (by Ecosystem),
    • 4.3.7 U.K.
      • 4.3.7.1 U.K. Precision Medicine Market (by Ecosystem),
    • 4.3.8 Spain
      • 4.3.8.1 Spain. Precision Medicine Market (by Ecosystem),
    • 4.3.9 Rest-of-Europe
      • 4.3.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)
  • 4.4 Asia-Pacific
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
      • 4.4.3.1 Asia-Pacific Precision Medicine Market (by Ecosystem)
    • 4.4.4 Japan
      • 4.4.4.1 Japan Precision Medicine Market (by Ecosystem
    • 4.4.5 China
      • 4.4.5.1 China Precision Medicine Market (by Ecosystem),
    • 4.4.6 India
      • 4.4.6.1 India Precision Medicine Market (by Ecosystem),
    • 4.4.7 Australia
      • 4.4.7.1 Australia Precision Medicine Market (by Ecosystem),
    • 4.4.8 South Korea
      • 4.4.8.1 South Korea. Precision Medicine Market (by Ecosystem)
    • 4.4.9 Rest-of-APAC
      • 4.4.9.1 Rest-of-APAC Precision Medicine Market (by Ecosystem)
  • 4.5 Latin America
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
      • 4.5.3.1 Latin America Precision Medicine Market (by Ecosystem)
    • 4.5.4 Brazil
      • 4.5.4.1 Brazil Precision Medicine Market (by Ecosystem)
    • 4.5.5 Mexico
      • 4.5.5.1 Mexico Precision Medicine Market (by Ecosystem),
    • 4.5.6 Rest-of-Latin America
      • 4.5.6.1 Rest-of-Latin America Precision Medicine Market (by Ecosystem),
  • 4.6 MEA
    • 4.6.1 Regional Overview
    • 4.6.2 Driving Factors for Market Growth
    • 4.6.3 Factors Challenging the Market
      • 4.6.3.1 Middle East and Africa Precision Medicine Market (by Ecosystem),
    • 4.6.4 K.S.A
      • 4.6.4.1 K.S.A Precision Medicine Market (by Ecosystem),
    • 4.6.5 South Africa
      • 4.6.5.1 South Africa Precision Medicine Market (by Ecosystem)
    • 4.6.6 Rest-of-MEA
      • 4.6.6.1 Rest of MEA Precision Medicine Market (by Ecosystem)

5 Competitive Landscape

  • 5.1 Competitive Landscape
    • 5.1.1 Synergistic Activities
  • 5.2 Company Profiles
    • 5.2.1 Abbott
      • 5.2.1.1 Overview
      • 5.2.1.2 Top Products
      • 5.2.1.3 Top Competitors
      • 5.2.1.4 Analyst View
    • 5.2.2 Thermo Fisher Scientific, Inc.
      • 5.2.2.1 Overview
      • 5.2.2.2 Top Products
      • 5.2.2.3 Top Competitors
      • 5.2.2.4 Analyst View
    • 5.2.3 Almac Group
      • 5.2.3.1 Overview
      • 5.2.3.2 Top Products/Services
      • 5.2.3.3 Top Competitors
      • 5.2.3.4 Analyst View
    • 5.2.4 ANGLE plc
      • 5.2.4.1 Overview
      • 5.2.4.2 Top Products
      • 5.2.4.3 Top Competitors
      • 5.2.4.4 Analyst View
    • 5.2.5 Astellas Pharma Inc
      • 5.2.5.1 Overview
      • 5.2.5.2 Top Products
      • 5.2.5.3 Top Competitors
      • 5.2.5.4 Analyst View
    • 5.2.6 Bio-Rad Laboratories, Inc.
      • 5.2.6.1 Overview
      • 5.2.6.2 Top Products
      • 5.2.6.3 Top Competitors
      • 5.2.6.4 Analyst View
    • 5.2.7 Epic Sciences
      • 5.2.7.1 Overview
      • 5.2.7.2 Top Products
      • 5.2.7.3 Top Competitors
      • 5.2.7.4 Analyst View
    • 5.2.8 F. Hoffmann-La Roche Ltd.
      • 5.2.8.1 Overview
      • 5.2.8.2 Top Products
      • 5.2.8.3 Top Competitors
      • 5.2.8.4 Analyst View
    • 5.2.9 Merck KGaA
      • 5.2.9.1 Overview
      • 5.2.9.2 Top Products
      • 5.2.9.3 Top Competitors
      • 5.2.9.4 Analyst View
    • 5.2.10 Illumina, Inc.
      • 5.2.10.1 Overview
      • 5.2.10.2 Top Products
      • 5.2.10.3 Top Competitors
      • 5.2.10.4 Analyst View
    • 5.2.11 QIAGEN N.V.
      • 5.2.11.1 Overview
      • 5.2.11.2 Top Products
      • 5.2.11.3 Top Competitors
      • 5.2.11.4 Analyst View
    • 5.2.12 Sysmex Corporation
      • 5.2.12.1 Overview
      • 5.2.12.2 Top Products
      • 5.2.12.3 Top Competitors
      • 5.2.12.4 Analyst View
    • 5.2.13 Laboratory Corporation of America Holdings
      • 5.2.13.1 Overview
      • 5.2.13.2 Top Products
      • 5.2.13.3 Top Competitors
      • 5.2.13.4 Analyst View
    • 5.2.14 Danaher Corporation
      • 5.2.14.1 Overview
      • 5.2.14.2 Top Products/ Services
      • 5.2.14.3 Top Competitors
      • 5.2.14.4 Analyst View
    • 5.2.15 Quest Diagnostics
      • 5.2.15.1 Overview
      • 5.2.15.2 Top Products
      • 5.2.15.3 Top Competitors
      • 5.2.15.4 Analyst View
    • 5.2.16 AstraZeneca
      • 5.2.16.1 Overview
      • 5.2.16.2 Top Products
      • 5.2.16.3 Top Competitors
      • 5.2.16.4 Analyst View
    • 5.2.17 ASURAGEN, INC
      • 5.2.17.1 Overview
      • 5.2.17.2 Top Products
      • 5.2.17.3 Top Competitors
      • 5.2.17.4 Analyst View
    • 5.2.18 bioMerieux SA
      • 5.2.18.1 Overview
      • 5.2.18.2 Top Products
      • 5.2.18.3 Top Competitors
      • 5.2.18.4 Analyst View
    • 5.2.19 Bristol-Myers Squibb
      • 5.2.19.1 Overview
      • 5.2.19.2 Top Products
      • 5.2.19.3 Top Competitors
      • 5.2.19.4 Analyst View
    • 5.2.20 Pacific Biosciences of California, Inc.
      • 5.2.20.1 Overview
      • 5.2.20.2 Top Products
      • 5.2.20.3 Top Competitors
      • 5.2.20.4 Analyst View
    • 5.2.21 Myriad Genetics, Inc.
      • 5.2.21.1 Overview
      • 5.2.21.2 Top Products
      • 5.2.21.3 Top Competitors
      • 5.2.21.4 Analyst View
    • 5.2.22 Teva Pharmaceuticals Industries Ltd.
      • 5.2.22.1 Overview
      • 5.2.22.2 Top Products
      • 5.2.22.3 Top Competitors
      • 5.2.22.4 Analyst View
    • 5.2.23 Sanofi S.A.
      • 5.2.23.1 Overview
      • 5.2.23.2 Top Products
      • 5.2.23.3 Top Competitors
      • 5.2.23.4 Analyst View
    • 5.2.24 Randox Laboratories Ltd.
      • 5.2.24.1 Overview
      • 5.2.24.2 Top Products
      • 5.2.24.3 Top Competitors
      • 5.2.24.4 Analyst View
    • 5.2.25 Eli Lilly and Company
      • 5.2.25.1 Overview
      • 5.2.25.2 Top Products
      • 5.2.25.3 Top Competitors
      • 5.2.25.4 Analyst View
    • 5.2.26 Pfizer Inc.
      • 5.2.26.1 Overview
      • 5.2.26.2 Top Products
      • 5.2.26.3 Top Competitors
      • 5.2.26.4 Analyst View
    • 5.2.27 Konica Minolta, Inc.
      • 5.2.27.1 Overview
      • 5.2.27.2 Top Products/Product Portfolio
      • 5.2.27.3 Top Competitors
      • 5.2.27.4 Analyst View
    • 5.2.28 Cardiff Oncology
      • 5.2.28.1 Overview
      • 5.2.28.2 Top Products
      • 5.2.28.3 Top Competitors
      • 5.2.28.4 Analyst View
    • 5.2.29 GE HealthCare
      • 5.2.29.1 Overview
      • 5.2.29.2 Top Products
      • 5.2.29.3 Top Competitors
      • 5.2.29.4 Analyst View
    • 5.2.30 Gilead Science, Inc.
      • 5.2.30.1 Overview
      • 5.2.30.2 Top Products
      • 5.2.30.3 Top Competitors
      • 5.2.30.4 Analyst View
    • 5.2.31 GSK plc
      • 5.2.31.1 Overview
      • 5.2.31.2 Top Products
      • 5.2.31.3 Top Competitors
      • 5.2.31.4 Analyst View
    • 5.2.32 Johnson & Johnson
      • 5.2.32.1 Overview
      • 5.2.32.2 Top Products
      • 5.2.32.3 Top Competitors
      • 5.2.32.4 Analyst View
    • 5.2.33 MDx Health, Inc.
      • 5.2.33.1 Overview
      • 5.2.33.2 Top Products
      • 5.2.33.3 Top Competitors
      • 5.2.33.4 Analyst View
    • 5.2.34 Novartis AG
      • 5.2.34.1 Overview
      • 5.2.34.2 Top Products
      • 5.2.34.3 Top Competitors
      • 5.2.34.4 Analyst View
    • 5.2.35 Oracle Corporation
      • 5.2.35.1 Overview
      • 5.2.35.2 Top Products
      • 5.2.35.3 Top Competitors
      • 5.2.35.4 Analyst View
    • 5.2.36 Menarini Silicon Biosystems
      • 5.2.36.1 Overview
      • 5.2.36.2 Top Products
      • 5.2.36.3 Top Competitors
      • 5.2.36.4 Analyst View

6 Research Methodology

  • 6.1 Global Precision Medicine Market: Research Methodology
    • 6.1.1 Data Sources
      • 6.1.1.1 Primary Data Sources
      • 6.1.1.2 Secondary Data Sources
    • 6.1.2 Data Triangulation
  • 6.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Precision Medicine Market, $Billion, 2023, 2028, and 2034
  • Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
  • Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
  • Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
  • Figure 5: Global Precision Medicine Market (by Region), $Billion, 2023, 2028, and 2034
  • Figure 6: Global Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
  • Figure 7: Global Precision Medicine Market (by Application), $Million, 2023, 2028, and 2034
  • Figure 8: Precision Medicine Approach
  • Figure 9: Evolution of Precision Medicine Technology
  • Figure 10: Precision Medicine: Enabling Technologies and Applications
  • Figure 11: Structured Big Data Reporting Benefits
  • Figure 12: Generalized Process for the Microarray
  • Figure 13: Stakeholders in Precision Medicine
  • Figure 14: Impact Analysis of Global Precision Medicine Market Factors, 2024-2034
  • Figure 15: Evolution of DNA Sequencing Technologies
  • Figure 16: Cost of Sequencing a Full Human Genome, 2001-2022
  • Figure 17: Prevalence of Cancer, in Millions, 2022 - 2035
  • Figure 18: Global Burden of Chronic Disease
  • Figure 19: Role of AI in Precision Medicine
  • Figure 20: Number of Patents Files, 2020-2024
  • Figure 21: Precision Medicine by Top Patent Owner
  • Figure 22: Precision Medicine: The Ecosystem
  • Figure 23: Global Precision Medicine Market (by Applied Sciences)
  • Figure 24: Global Precision Medicine Market (by Applied Sciences), $Billion, 2023-2034
  • Figure 25: Precision Medicine: Multi-omics Sciences
  • Figure 26: Precision Medicine: Genomics
  • Figure 27: Global Precision Medicine Market (by Applied Science) (Genomics) $Billion, 2023-2034
  • Figure 28: Global Precision Medicine PCR Market, $Billion, 2023-2034
  • Figure 29: Global Precision Medicine PCR Market (by Product) $Billion, 2023-2034
  • Figure 30: Global Precision Medicine PCR Market (by End User) $Billion, 2023-2034
  • Figure 31: Global Precision Medicine PCR Market (by Region) $Billion, 2023-2034
  • Figure 32: Evolution of Next-Generation Sequencing
  • Figure 33: Global Precision Medicine NGS Market, $Billion, 2023-2034
  • Figure 34: Global Precision Medicine NGS Market (by Product), $Billion, 2023-2034
  • Figure 35: Global Precision Medicine NGS Market (by Technology), $Billion, 2023-2034
  • Figure 36: Global Precision Medicine NGS Market (by End User), $Billion, 2023-2034
  • Figure 37: Global Precision Medicine NGS Market (by Region), $Billion, 2023-2034
  • Figure 38: Global Precision Medicine Genome Editing Market, $Billion, 2023-2034
  • Figure 39: Global Precision Medicine Genome Editing Market (by Product), $Billion, 2023-2034
  • Figure 40: Global Precision Medicine Genome Editing Market (by End User), $Billion, 2023-2034
  • Figure 41: Global Precision Medicine Genome Editing Market (by Region), $Billion, 2023-2034
  • Figure 42: Global Precision Medicine Other Technologies Market, $Billion, 2023-2034
  • Figure 43: Global Precision Medicine Other Technologies Market (by Region), $Billion, 2023-2034
  • Figure 44: Role of Biomarkers in Pharmacogenomics
  • Figure 45: Role of FDA In Pharmacogenomics
  • Figure 46: Global Precision Medicine Market (by Applied Science) (by Pharmacogenomics), $Billion, 2023-2034
  • Figure 47: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), $Billion, 2023-2034
  • Figure 48: Global Precision Medicine Pharmacogenomics Market (by End User), $Billion, 2023-2034
  • Figure 49: Global Precision Medicine Pharmacogenomics Market (by Region), $Billion, 2023-2034
  • Figure 50: Global Precision Medicine Market (by Applied Science) (by Others), $Billion, 2023-2034
  • Figure 51: Precision Medicine: Diagnostics
  • Figure 52: Global Precision Medicine Market (by Precision Diagnostic)
  • Figure 53: Global Precision Medicine Market (by Precision Diagnostics), $Billion, 2023-2034
  • Figure 54: Global Precision Medicine Market (by Precision Diagnostics) (by Type), $Billion, 2023-2034
  • Figure 55: General Workflow of a Molecular Diagnostic Assay
  • Figure 56: Global Precision Medicine Market (by Molecular Diagnostics)
  • Figure 57: Global Precision Medicine Market (by Precision Diagnostics) (by Molecular Diagnostics) $Billion, 2023-2034
  • Figure 58: Global Precision Medicine Market (by Molecular Diagnostics)(by Type), $Billion, 2023-2034
  • Figure 59: Benefits and Risks Associated with NIPT
  • Figure 60: Global Precision Medicine NIPT Market, $Billion, 2023-2034
  • Figure 61: Global Precision Medicine NIPT Market (by Platform)$Billion, 2023-2034
  • Figure 62: Global Precision Medicine NIPT Market (by Region), $Billion, 2023-2034
  • Figure 63: Drug and Companion Diagnostics Development Process
  • Figure 64: Benefits and Risks Associated with Companion Diagnostics
  • Figure 65: Global Precision Medicine Companion Diagnostics Market, $Billion, 2023-2034
  • Figure 66: Global Precision Medicine Companion Diagnostics Market (by Technology), $Billion, 2023-2034
  • Figure 67: Global Precision Medicine Companion Diagnostics Market (by Indication), $Billion, 2023-2034
  • Figure 68: Global Precision Medicine Companion Diagnostics Market (by Region), $Billion, 2023-2034
  • Figure 69: Clinical Applications of Liquid Biopsy
  • Figure 70: Global Precision Medicine Liquid Biopsy Market, $Billion, 2023-2034
  • Figure 71: Global Precision Medicine Liquid Biopsy Market (by Indication), $Billion, 2023-2034
  • Figure 72: Global Precision Medicine Liquid Biopsy Market (by Region), $Billion, 2023-2034
  • Figure 73: Global Precision Medicine Other Molecular Diagnostics Market, $Billion, 2023-2034
  • Figure 74: Global Precision Medicine Other Molecular Diagnostics Market (by Type), $Billion, 2023-2034
  • Figure 75: Global Precision Medicine Other Molecular Diagnostics Market (by Region), $Billion, 2023-2034
  • Figure 76: Global Precision Medicine Market (by Precision Diagnostics) (by Medical Imaging) $Billion, 2023-2034
  • Figure 77: Global Precision Medicine Market (by Precision Diagnostics) (by Medical Imaging) (by Type), $Billion, 2023-2034
  • Figure 78: Global Precision Medicine Imaging Analytics Market, $Billion, 2023-2034
  • Figure 79: Global Precision Medicine CADx Market, Billion,2023-2034
  • Figure 80: Global Precision Medicine Market (by Precision Diagnostics) (by Medical Imaging) (by Region), $Billion, 2023-2034
  • Figure 81: Global Precision Medicine Digital Health and Information Technology Market, $Billion, 2023-2034
  • Figure 82: Global Precision Medicine Digital Health and Information Technology Market (by Type), $Billion, 2023-2034
  • Figure 83: Global Precision Medicine Market (by Digital Health and Information Technology) (by CDSS) $Billion, 2023-2034
  • Figure 84: Big Data Attributes
  • Figure 85: Global Precision Medicine Market (by Digital Health and Information Technology) (by Big Data Analytics) $Billion, 2023-2034
  • Figure 86: Big Data Analytics: Key Benefits
  • Figure 87: Global Precision Medicine Market (by Digital Health and Information Technology) (by IT Infrastructure) $Billion, 2023-2034
  • Figure 88: Global Precision Medicine Market (by Digital Health and Information Technology) (by IT Infrastructure) (by Type) $Billion, 2023-2034
  • Figure 89: Global Precision Medicine Market (by Digital Health and Information Technology) (by Genomics Informatics) $Billion, 2023-2034
  • Figure 90: Global Precision Medicine Market (by Digital Health and Information Technology) (by Genomics Informatics) (by Product Type) $Billion, 2023-2034
  • Figure 91: Global Precision Medicine Market (by Digital Health and Information Technology) (by In-silico Informatics) $Billion, 2023-2034
  • Figure 92: Global Precision Medicine Market (by Digital Health and Information Technology) (by Mobile Health) $Billion, 2023-2034
  • Figure 93: Global Precision Medicine Market (by Digital Health and Information Technology Market) (by End User), $Billion, 2023-2034
  • Figure 94: Global Precision Medicine Market (by Digital Health and Information Technology (by Region), $Billion, 2023-2034
  • Figure 95: Global Precision Medicine Market (by Precision Therapeutics) $Billion, 2023-2034
  • Figure 96: Global Precision Medicine Market (by Precision Therapeutics) $Billion, 2023-2034
  • Figure 97: Global Precision Medicine Market (by Precision Therapeutics) (by Clinical Trials) $Billion, 2023-2034
  • Figure 98: Global Precision Medicine Market (by Precision Therapeutics) (by Clinical Trials) (by Region), $Billion, 2023-2034
  • Figure 99: Types of Cell Therapy
  • Figure 100: Global Precision Medicine Market (by Precision Therapeutics) (by Cell Therapy), $Billion, 2023-2034
  • Figure 101: Global Precision Medicine Market (by Precision Therapeutics) (by Cell Therapy) (by Region), $Billion, 2023-2034
  • Figure 102: Global Precision Medicine Market (by Precision Therapeutics) (by Drug Discovery and Research) $Billion, 2023-2034
  • Figure 103: Global Precision Medicine Market (by Precision Therapeutics) (by Drug Discovery and Research) (by Region), $Billion, 2023-2034
  • Figure 104: Types of Gene Therapy
  • Figure 105: Types of Gene Therapy
  • Figure 106: Global Precision Medicine Market (by Precision Therapeutics) (by Gene Therapy), $Billion, 2023-2034
  • Figure 107: Global Precision Medicine Market (by Precision Therapeutics) (by Gene Therapy) (by Region), $Billion, 2023-2034
  • Figure 108: Types of Cancer
  • Figure 109: Global Precision Medicine Market (by Oncology), $Billion, 2023-2034,
  • Figure 110: Global Precision Medicine Market (by Infectious Diseases) $Billion, 2023-2034
  • Figure 111: Number of Deaths by Top 4 Infectious Diseases, 2022
  • Figure 112: Global Precision Medicine Market (by Neurology), $Billion, 2023-2034
  • Figure 113: Global Precision Medicine Market (by Cardiovascular Disease), $Billion, 2023-2034
  • Figure 114: Global Precision Medicine Market (by Lifestyle and Endocrinology), $Billion, 2023-2034
  • Figure 115: Global Precision Medicine Market (by Gastroenterology) $Billion, 2023-2034
  • Figure 116: Global Precision Medicine Market (by Other Application) Market, $Billion, 2023-2034
  • Figure 117: North America Precision Medicine Market, $Billion, 2023-2034
  • Figure 118: U.S. Precision Medicine Market, $Billion, 2023-2034
  • Figure 119: Canada Precision Medicine Market, $Billion, 2023-2034
  • Figure 120: Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 121: Germany Precision Medicine Market, $Billion, 2023-2034
  • Figure 122: France Precision Medicine Market, $Billion, 2023-2034
  • Figure 123: Italy Precision Medicine Market, $Billion, 2023-2034
  • Figure 124: U.K. Precision Medicine Market, $Billion, 2023-2034
  • Figure 125: Spain Precision Medicine Market, $Billion, 2023-2034
  • Figure 126: Rest of Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 127: Asia-Pacific Precision Medicine Market, $ Billion, 2023-2034
  • Figure 128: Japan Precision Medicine Market, $Billion, 2023-2034
  • Figure 129: China Precision Medicine Market, $Billion, 2023-2034
  • Figure 130: India Precision Medicine Market, $Billion, 2023-2034
  • Figure 131: Australia Precision Medicine Market, $Billion, 2023-2034
  • Figure 132: South Korea Precision Medicine Market, $Billion, 2023-2034
  • Figure 133: Rest-of-APAC Precision Medicine Market, $Billion, 2023-2034
  • Figure 134: Latin America Precision Medicine Market $Billion,2023-2034
  • Figure 135: Brazil Precision Medicine Market, $Billion, 2023-2034
  • Figure 136: Mexico Precision Medicine Market, $Billion, 2023-2034
  • Figure 137: Rest-of-Latin America Precision Medicine Market, $Billion, 2023-2034
  • Figure 138: Middle East and Africa Precision Medicine Market, $Billion, 2023-2034
  • Figure 139: K.S.A Precision Medicine Market, $Billion, 2023-2034
  • Figure 140: South Africa Precision Medicine Market, $Billion, 2023-2034
  • Figure 141: Rest-of-MEA Precision Medicine Market, $Billion 2023-2034
  • Figure 142: Synergistic Activities, by Company (January 2020- January 2025)
  • Figure 143: Synergistic Activities, by Type (January 2020- January 2025)
  • Figure 144: Data Triangulation
  • Figure 145: Top-Down and Bottom-Up Approach

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Application
  • Table 3: Pipeline Analysis (by Company)
  • Table 4: Pipeline Analysis (by Product)
  • Table 5: Precision Medicine Drugs Pipeline Analysis
  • Table 6: Ecosystem Summary
  • Table 7: List of Few FDA-Approved Pharmacogenomics Biomarkers in Drug Labeling
  • Table 8: Key Approved Therapeutics with FDA-Mandated Companion Diagnostics Tests
  • Table 9: List of FDA-Approved Companion Diagnostics
  • Table 10: Commercially Available Primary and Secondary Analysis Tools Providers
  • Table 11: Product Summary
  • Table 12: Cancer Precision Medicine Drugs and Indications
  • Table 13: Infectious Diseases Precision Medicine Drugs and Indications
  • Table 14: Neurology Precision Medicine Drugs and Indications
  • Table 15: Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • Table 16: Endocrinology Precision Medicine Drugs and Indications
  • Table 17: Gastroenterology Precision Medicine Drugs and Indications
  • Table 18: Precision Drugs for Other Applications
  • Table 19: Global Precision Medicine Market (by Region), $Million, 2023-2034
  • Table 20: North America Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 21: U.S. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 22: Canada Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 23: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 24: Germany Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 25: France Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 26: Italy Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 27: Funding Scenario in Universities
  • Table 28: U.K. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 29: Spain. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 30: Rest-of-Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 31: Asia-Pacific Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 32: Japan Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 33: China Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 34: India Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 35: Australia Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 36: South Korea. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 37: Rest-of-APAC Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 38: Latin America Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 39: Brazil Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 40: Mexico Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 41: Rest-of-Latin America Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 42: Middle East and Africa Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 43: K.S.A Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 44: South Africa Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 45: Rest-of-MEA Precision Medicine Market (by Ecosystem), $Billion, 2023-2034